Drug Profile

SC 101 - Tianjin ConjuStar Biologics

Alternative Names: SC-101 - Tianjin ConjuStar Biologics

Latest Information Update: 30 Jul 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

23 Jul 2025 Tianjin ConjuStar Biologics plans a phase II trial for Breast cancer and Triple-negative breast cancer (Late-stage disease, Metastatic disease, Monotherapy) (IV) in July 2025 (NCT07080619)
27 Feb 2024 Phase-I clinical trials in Solid tumours (Late-stage disease, Metastatic disease) in China (IV) (NCT06220838)
25 Jan 2024 Preclinical trials in Solid tumours in China (IV) prior to January 2024 (Tianjin ConjuStar Biologics pipeline, January 2024)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com